Pfizer and BioNTech announced on Thursday evening that they had submitted an application to the Food and Drug Administration (FDA) seeking full approval for the administration of their two-dose COVID-19 vaccine in children aged between 12 and 15.
This practice of extending shelf life for Pfizer shots is endorsed by health authorities worldwide, including US FDA, EMA, and WHO, provided that the ultra low-temperature storage conditions of the vaccines are guaranteed.